Enterococcus Faecium

Allergen Immunotherapy

Dosage for Enterococcus Faecium as an allergenic extract is highly individualized and is not measured in milligrams, but rather in 'Noon Units,' 'Protein Nitrogen Units' (PNU), or Weight/Volume (w/v) dilutions.

• Escalation Phase: Usually starts with a very dilute solution (e.g., 1:100,000 w/v). Injections are given 1–2 times per week, with the concentration increasing gradually.
• Maintenance Phase: Once the 'top dose' is reached (often 1:100 or 1:10 w/v), injections are spaced out to every 2–4 weeks. The specific volume typically ranges from 0.1 mL to 0.5 mL per injection.

Probiotic Use

• Standard Dose: 1 capsule containing approximately 75 million to 1 billion CFUs, taken 1 to 3 times daily.
• Antibiotic-Associated Diarrhea: Healthcare providers may recommend 1 dose twice daily, taken at least 2 hours apart from the antibiotic dose.

Allergen Immunotherapy

• Children (5 years and older): Dosing follows the adult escalation protocol but may proceed more cautiously. Safety and efficacy in children under 5 years of age for bacterial allergenic extracts have not been robustly established.

Probiotic Use

• Infants and Children: Specific pediatric formulations or powder packets are used. Doses are typically lower, such as 5 million to 10 million CFUs per day, and must be administered under strict pediatric supervision.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the organism and its antigens are not cleared by the kidneys in a manner that would lead to systemic toxicity.

Hepatic Impairment

No dosage adjustments are necessary for patients with liver disease. However, patients with end-stage liver disease (cirrhosis) may be at higher risk for bacterial translocation and should use live probiotics with extreme caution.

Elderly Patients

Elderly patients generally follow standard dosing. However, the clinician must assess the patient's overall immune status, as the risk of opportunistic infection from live bacteria increases with age-related immunosenescence.

For Injections (Immunotherapy)

• Administration: Must be administered subcutaneously (under the skin) by a healthcare professional in a clinical setting equipped to handle anaphylaxis.
• Observation: Patients must remain in the office for at least 30 minutes following the injection to monitor for serious allergic reactions.
• Storage: Vials must be refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.

For Oral Forms (Probiotics)

• Timing: Can be taken with or without food. However, taking it with a light meal may help the bacteria survive the journey through the stomach.
• Consistency: Take at the same time each day to maintain stable colonization levels.
• Avoid Heat: Do not mix powders with very hot liquids or foods, as high temperatures can kill the live bacteria.

• Immunotherapy: If you miss an injection, contact your allergist. If the delay is significant, the doctor may need to reduce the dose for the next injection to ensure safety.
• Oral Probiotic: Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double the dose to catch up.

• Signs of Overdose: In the context of immunotherapy, an overdose typically manifests as a severe systemic allergic reaction (hives, wheezing, swelling, drop in blood pressure). For oral probiotics, an 'overdose' usually results in mild gastrointestinal distress, such as bloating, gas, or cramping.
• Emergency Measures: If a systemic reaction occurs after an injection, epinephrine is the first-line treatment. For oral overdose, supportive care and hydration are usually sufficient.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

When Enterococcus Faecium is administered as an allergenic extract via injection, the most common side effects are localized to the injection site. These include:

• Local Swelling (Wheal): A raised, red bump at the site of injection, often appearing within minutes and lasting several hours.
• Erythema (Redness): Redness surrounding the injection site that may feel warm to the touch.
• Pruritus (Itching): Intense itching at the injection site, which is a sign of the localized immune response.

For oral probiotic forms, common side effects include:

• Flatulence (Gas): Increased gas production as the bacteria ferment fibers in the gut.
• Abdominal Bloating: A feeling of fullness or distension in the stomach area.

• Mild Systemic Reactions: Some patients may experience a 'flu-like' feeling, low-grade fever, or general malaise for 24 hours after an immunotherapy injection.
• Changes in Bowel Habits: Some patients may experience mild constipation or a temporary increase in stool frequency when starting oral therapy.
• Headache: Occasional reports of mild headaches have been noted during the initial phase of treatment.

• Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the armpit if the injection was in the upper arm).
• Urticaria (Hives): Generalized hives appearing on parts of the body away from the injection site.
• Bacteremia: In extremely rare cases, particularly in patients with undiagnosed heart valve issues or severe immunosuppression, the bacteria can enter the bloodstream.

> Warning: Stop taking Enterococcus Faecium and call your doctor immediately if you experience any of these.

• Anaphylaxis: This is a life-threatening allergic reaction. Symptoms include a sudden drop in blood pressure, rapid or weak pulse, narrowing of the airways (wheezing), and swelling of the tongue or throat.
• Angioedema: Severe swelling beneath the skin, particularly around the eyes, lips, or throat.
• Septicemia: Signs include high fever, chills, rapid breathing, and confusion. This is more likely in patients with central venous catheters or compromised immune systems.
• Chest Pain or Shortness of Breath: Could indicate a severe systemic reaction or, in rare cases, endocarditis (inflammation of the heart lining) if the bacteria colonize heart valves.

• Sensitization: There is a theoretical risk that long-term use of allergenic extracts could lead to increased sensitivity to the antigen, though the goal of therapy is the opposite (desensitization).
• Antibiotic Resistance: A significant concern with Enterococcus Faecium is its ability to acquire resistance genes. Long-term colonization with certain strains could potentially serve as a reservoir for Vancomycin-Resistant Enterococci (VRE), although medical-grade strains (like SF68) are screened for these genes.
• Autoimmune Triggering: There is ongoing research into whether chronic immune stimulation via bacterial extracts could trigger or exacerbate certain autoimmune conditions in genetically predisposed individuals.

No FDA black box warnings currently exist for Enterococcus Faecium allergenic extracts. However, all allergenic extracts carry a general warning regarding the risk of severe non-fatal and fatal systemic allergic reactions. These products should only be administered by clinicians prepared to manage anaphylaxis.

Report any unusual symptoms to your healthcare provider. Monitoring of the injection site for delayed-type hypersensitivity (swelling that appears 24–48 hours later) is also recommended.

Enterococcus Faecium products, whether used as probiotics or allergenic extracts, must be used with caution in specific clinical scenarios. The most critical safety consideration is the patient's immune status. Because these products contain biological material or live organisms, they pose a risk of opportunistic infection in vulnerable populations. Patients must inform their healthcare provider of any history of heart valve disease, as Enterococci are a leading cause of bacterial endocarditis.

No FDA black box warnings for Enterococcus Faecium. However, the FDA requires all allergenic extracts to include a warning that they can cause severe anaphylaxis. The labeling emphasizes that these products are intended for use only by physicians who are experienced in the administration of allergenic extracts and the management of allergic emergencies.

• Allergic Reactions / Anaphylaxis Risk: The risk of a systemic reaction is highest during the escalation phase of immunotherapy. Patients with unstable asthma are at a significantly higher risk for fatal reactions and should not start immunotherapy until their asthma is well-controlled.
• Infectious Risk: In patients with compromised intestinal barriers (e.g., Crohn's disease, ulcerative colitis), there is a risk that live E. faecium could translocate from the gut into the bloodstream, leading to sepsis.
• VRE Risk: Healthcare providers must ensure that the strain of E. faecium used (especially in probiotics) is not Vancomycin-Resistant Enterococcus (VRE). VRE is a major hospital-acquired pathogen that is difficult to treat.
• Heart Valve Disease: Patients with prosthetic heart valves or a history of endocarditis should avoid live Enterococcus probiotics unless specifically cleared by a cardiologist.

• Post-Injection Observation: A mandatory 30-minute wait time in the clinic after every injection.
• Immune Function: Periodic assessment of the patient's immune status if they are on long-term therapy.
• Bowel Health: For those taking oral forms, any development of bloody stools or severe abdominal pain requires immediate investigation.
• Peak Flow Monitoring: For asthmatic patients receiving injections, monitoring peak expiratory flow before each dose is recommended.

Enterococcus Faecium generally does not affect the ability to drive or operate machinery. However, if a patient experiences a systemic allergic reaction or receives epinephrine to treat a reaction, they should not drive until they are fully recovered and cleared by a medical professional.

There are no direct pharmacological interactions between Enterococcus Faecium and alcohol. However, alcohol can cause vasodilation, which might theoretically increase the rate of absorption of an injected allergenic extract, potentially increasing the risk of a systemic reaction. It is best to avoid alcohol for several hours before and after an immunotherapy injection.

• Immunotherapy: Stopping treatment abruptly will result in the loss of the desensitization effect. If therapy is paused for more than a few weeks, the dose must usually be 'reset' to a lower level to avoid reactions.
• Probiotics: Can be stopped without a tapering period. However, the beneficial effects on the gut microbiome will typically fade within 7 to 14 days as the strain is cleared from the system.

> Important: Discuss all your medical conditions with your healthcare provider before starting Enterococcus Faecium.

• Live Vaccines: If you are receiving live Enterococcus Faecium (probiotic), you should consult your doctor before receiving live attenuated vaccines (e.g., oral typhoid vaccine). There is a theoretical risk that the probiotic could interfere with the replication of the vaccine strain in the gut.
• Immunosuppressants (High-Dose): Patients on high-dose chemotherapy or systemic corticosteroids should not use live E. faecium due to the risk of systemic infection (bacteremia).

• Antibiotics: Since Enterococcus Faecium is a bacterium, most antibiotics will kill it. If taking a probiotic form, the efficacy will be significantly reduced if taken simultaneously with antibiotics. Examples include:
• Vancomycin: Highly effective against most E. faecium (unless VRE).
• Linezolid and Daptomycin: Used for resistant strains; will eliminate the probiotic organism.
• Amoxicillin: Frequently used and will inhibit E. faecium growth.
• Management: Space the probiotic dose and the antibiotic dose by at least 2 to 3 hours.

• Antifungals: While E. faecium is a bacterium, some antifungal medications can alter the gut environment, indirectly affecting the colonization success of the probiotic.
• Other Allergenic Extracts: When multiple allergenic extracts (e.g., pollen, dust mite, and bacteria) are mixed in the same syringe, there is a risk of proteolytic enzymes in one extract degrading the proteins in another. This can reduce the efficacy of the Enterococcus Faecium extract.

• High-Fiber Diets: May actually enhance the effect of E. faecium probiotics, as fiber acts as a 'prebiotic' (food for the bacteria).
• Hot Beverages: Taking oral E. faecium with very hot coffee or tea can kill the live bacteria before they reach the gut.
• Dairy: Some evidence suggests that dairy products may help buffer the bacteria against stomach acid, potentially improving survival.

• Prebiotics (Inulin, FOS): These supplements are often taken with E. faecium to improve its growth and activity in the colon.
• Antibacterial Herbs: Herbs with known antimicrobial properties, such as oil of oregano, goldenseal (berberine), or garlic, may reduce the viability of the probiotic if taken in high doses concurrently.

• Stool Cultures: If you are taking Enterococcus Faecium probiotics, it may show up in stool culture tests. Inform the laboratory and your doctor so they do not mistake the probiotic strain for a pathogenic infection.
• Skin Prick Tests: Taking antihistamines (like loratadine or cetirizine) will interfere with the diagnostic skin testing for Enterococcus Faecium, leading to a false-negative result. Antihistamines should typically be stopped 3 to 7 days before testing.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe Immunodeficiency: Patients with HIV/AIDS (low CD4 count), those undergoing bone marrow transplants, or those with primary immunodeficiency disorders must not use live Enterococcus Faecium products. The risk of life-threatening sepsis is too high.
• Acute Infection: Immunotherapy injections should not be given during an acute febrile illness or active infection, as this can increase the risk of a systemic reaction.
• Uncontrolled Asthma: Patients with an FEV1 (Forced Expiratory Volume) consistently below 70% of predicted value should not receive allergenic extracts due to the risk of fatal bronchospasm.
• Hypersensitivity to Diluents: Some extracts contain phenol or glycerin as preservatives. Patients with a known severe allergy to these components should not receive the injection.

• Pregnancy: While not strictly contraindicated, starting a new course of immunotherapy during pregnancy is generally avoided. If a patient is already on a stable maintenance dose, it may be continued with caution.
• Beta-Blocker Therapy: Patients taking beta-blockers (e.g., metoprolol, propranolol) may be resistant to the effects of epinephrine, making the treatment of an accidental anaphylactic reaction much more difficult.
• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis should be evaluated carefully, as immune stimulation could potentially cause a flare.

• Other Enterococci: Patients allergic to Enterococcus Faecium may also react to Enterococcus faecalis or other related Group D Streptococci.
• Bacterial Lysates: There may be cross-reactivity with multi-bacterial vaccines that contain various respiratory pathogens.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Enterococcus Faecium.

• Pregnancy Category: The FDA does not assign standard letter categories (A, B, C, D, X) to allergenic extracts.
• Risk Summary: There are no adequate and well-controlled studies of Enterococcus Faecium in pregnant women. For probiotics, E. faecium is generally considered safe as it is a natural commensal, but it should only be used if clearly needed. For immunotherapy, the primary risk is maternal anaphylaxis, which can cause fetal hypoxia (lack of oxygen).
• Recommendation: Most allergists recommend against initiating immunotherapy during pregnancy but may continue maintenance doses if the benefit outweighs the risk.

• Passage into Milk: It is highly unlikely that Enterococcus Faecium antigens or the live bacteria enter breast milk in significant quantities.
• Safety: Probiotic use is generally considered safe during breastfeeding and may even have beneficial effects on the infant's developing microbiome via the entero-mammary pathway. No adverse effects have been reported in nursing infants whose mothers were receiving allergenic extracts.

• Approval: Probiotic use is common in children for diarrhea management. However, the use of E. faecium as an allergenic extract is typically reserved for children 5 years of age and older who can communicate symptoms of a systemic reaction.
• Precautions: In infants, the use of probiotics must be carefully monitored due to the risk of d-lactic acidosis (though more common with other species) and the risk of translocation in premature neonates.

• Considerations: The elderly are at a higher risk for polypharmacy and may be taking medications like beta-blockers or ACE inhibitors that complicate the management of allergic reactions.
• Renal/Hepatic: No specific changes in E. faecium handling are expected, but the underlying vulnerability to infection must be assessed.

• Dosing: No adjustments required. E. faecium is not systemically absorbed in healthy individuals, and its metabolites are not known to be nephrotoxic.

• Dosing: No adjustments required. However, clinicians should monitor for signs of spontaneous bacterial peritonitis (SBP) in patients with cirrhosis, as any live bacterial supplement carries a theoretical risk in this population.

> Important: Special populations require individualized medical assessment.

Enterococcus Faecium acts as a biological response modifier. In the gastrointestinal tract, it utilizes the 'SF68' strain's ability to produce lactic acid and bacteriocins, which inhibit the growth of pathogenic bacteria like Clostridium difficile and Salmonella. It also enhances the intestinal barrier function by upregulating tight junction proteins.

In the context of immunotherapy (Non-Standardized Plant Allergenic Extract [EPC]), the mechanism involves 'Immune Deviation.' The repeated exposure to bacterial antigens leads to the induction of IL-10 and TGF-beta producing regulatory T-cells. These cells suppress the Th2 allergic response and promote the production of IgG4, which acts as a competitive inhibitor, preventing IgE from binding to the allergen.

• Onset of Action: For diarrhea, effects are often seen within 24–48 hours. For immunotherapy, clinical desensitization typically takes 6 months to 1 year of consistent treatment.
• Duration of Effect: Probiotic effects last only as long as the organism colonizes the gut (usually 1–2 weeks post-discontinuation). Immunotherapy effects can last for several years after a 3–5 year course of treatment is completed.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local GI action) |

| Protein Binding | N/A |

| Half-life | 12-24 hours (Bacterial doubling time) |

| Tmax | 4-6 hours (Peak GI concentration) |

| Metabolism | Bacterial fermentation |

| Excretion | Fecal (100%) |

• Biological Nature: Gram-positive cocci, occurring in pairs or short chains. It is a facultative anaerobe, meaning it can grow with or without oxygen.
• Genomic Characteristics: Known for a highly plastic genome, allowing it to adapt to various environments and acquire resistance genes (e.g., vanA or vanB for vancomycin resistance).
• Solubility: Allergenic extracts are typically prepared in aqueous solutions containing 0.9% saline and 0.4% phenol.

• Primary Class: Non-Standardized Plant Allergenic Extract [EPC].
• Secondary Class: Probiotic; Biological Response Modifier.